177 related articles for article (PubMed ID: 38125518)
1. A precise prognostic signature in CTNNB1-mutant hepatocellular carcinoma: Prognosis prediction and precision treatment exploration.
Wang J; Zhu G
Heliyon; 2023 Dec; 9(12):e22382. PubMed ID: 38125518
[TBL] [Abstract][Full Text] [Related]
2. A novel prognostic signature contributes to precision treatment in colon adenocarcinoma with KRAS mutation.
Dong W; Zhang H; Li Q; Guan N; Yun C; Zhao H; Zhang F; Zeng Z; Hu Y; Li Q; Yang J; Ma Z; Chen M; Xiao W
Eur J Cancer Prev; 2023 Nov; 32(6):557-565. PubMed ID: 37310401
[TBL] [Abstract][Full Text] [Related]
3. A novel strategy for precise prognosis management and treatment option in colon adenocarcinoma with TP53 mutations.
Niu L; Liu L; Cai J
Front Surg; 2023; 10():1079129. PubMed ID: 36843983
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of a CTNNB1-associated metabolic prognostic model for hepatocellular carcinoma.
Huo J; Wu L; Zang Y
J Cell Mol Med; 2021 Jan; 25(2):1151-1165. PubMed ID: 33300278
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive analysis of immune-related gene signature based on ssGSEA algorithms in the prognosis and immune landscape of hepatocellular carcinoma.
Wang L; Wang L; He P
Front Genet; 2022; 13():1064432. PubMed ID: 36568383
[No Abstract] [Full Text] [Related]
6. Construction and Validation of a Prognostic Gene-Based Model for Overall Survival Prediction in Hepatocellular Carcinoma Using an Integrated Statistical and Bioinformatic Approach.
Dessie EY; Tu SJ; Chiang HS; Tsai JJP; Chang YS; Chang JG; Ng KL
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33562824
[TBL] [Abstract][Full Text] [Related]
7. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of a robust epithelial-mesenchymal transition (EMT)-related prognostic signature for hepatocellular carcinoma.
Chen S; Zhao E
Clin Res Hepatol Gastroenterol; 2021 Sep; 45(5):101587. PubMed ID: 33662631
[TBL] [Abstract][Full Text] [Related]
9. An immune infiltration-related long non-coding RNAs signature predicts prognosis for hepatocellular carcinoma.
Li G; Xu S; Yang S; Wu C; Zhang L; Wang H
Front Genet; 2022; 13():1029576. PubMed ID: 36568382
[No Abstract] [Full Text] [Related]
10. AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation.
Abitbol S; Dahmani R; Coulouarn C; Ragazzon B; Mlecnik B; Senni N; Savall M; Bossard P; Sohier P; Drouet V; Tournier E; Dumont F; Sanson R; Calderaro J; Zucman-Rossi J; Vasseur-Cognet M; Just PA; Terris B; Perret C; Gilgenkrantz H
J Hepatol; 2018 Jun; 68(6):1203-1213. PubMed ID: 29525529
[TBL] [Abstract][Full Text] [Related]
11. A stemness-based eleven-gene signature correlates with the clinical outcome of hepatocellular carcinoma.
Hong L; Zhou Y; Xie X; Wu W; Shi C; Lin H; Shi Z
BMC Cancer; 2021 Jun; 21(1):716. PubMed ID: 34147074
[TBL] [Abstract][Full Text] [Related]
12. Identification of an Epithelial-Mesenchymal Transition-Related Long Non-coding RNA Prognostic Signature to Determine the Prognosis and Drug Treatment of Hepatocellular Carcinoma Patients.
Huang S; Li D; Zhuang L; Zhang J; Wu J
Front Med (Lausanne); 2022; 9():850343. PubMed ID: 35685422
[TBL] [Abstract][Full Text] [Related]
13. Nuclear factor erythroid 2-related factor 2 and β-Catenin Coactivation in Hepatocellular Cancer: Biological and Therapeutic Implications.
Tao J; Krutsenko Y; Moghe A; Singh S; Poddar M; Bell A; Oertel M; Singhi AD; Geller D; Chen X; Lujambio A; Liu S; Monga SP
Hepatology; 2021 Aug; 74(2):741-759. PubMed ID: 33529367
[TBL] [Abstract][Full Text] [Related]
14. Bioinformatics Analysis Identifies Precision Treatment with Paclitaxel for Hepatocellular Carcinoma Patients Harboring Mutant
Lin JC; Liu TP; Andriani V; Athoillah M; Wang CY; Yang PM
J Pers Med; 2021 Nov; 11(11):. PubMed ID: 34834551
[TBL] [Abstract][Full Text] [Related]
15. Characterizing the key genes of COVID-19 that regulate tumor immune microenvironment and prognosis in hepatocellular carcinoma.
Gao S; Zhang L; Wang H
Funct Integr Genomics; 2023 Aug; 23(3):262. PubMed ID: 37540264
[TBL] [Abstract][Full Text] [Related]
16. Development and Validation of a Prognostic Signature Associated With Tumor Microenvironment Based on Autophagy-Related lncRNA Analysis in Hepatocellular Carcinoma.
Deng Y; Zhang F; Sun ZG; Wang S
Front Med (Lausanne); 2021; 8():762570. PubMed ID: 34970559
[No Abstract] [Full Text] [Related]
17. A novel signature incorporating lipid metabolism- and immune-related genes to predict the prognosis and immune landscape in hepatocellular carcinoma.
Yang T; Luo Y; Liu J; Liu F; Ma Z; Liu G; Li H; Wen J; Chen C; Zeng X
Front Oncol; 2023; 13():1182434. PubMed ID: 37346073
[TBL] [Abstract][Full Text] [Related]
18. Identification of a six-gene signature predicting overall survival for hepatocellular carcinoma.
Liu GM; Zeng HD; Zhang CY; Xu JW
Cancer Cell Int; 2019; 19():138. PubMed ID: 31139015
[TBL] [Abstract][Full Text] [Related]
19. A novel five-gene signature predicts overall survival of patients with hepatocellular carcinoma.
Wang Z; Pan L; Guo D; Luo X; Tang J; Yang W; Zhang Y; Luo A; Gu Y; Pan Y
Cancer Med; 2021 Jun; 10(11):3808-3821. PubMed ID: 33934539
[TBL] [Abstract][Full Text] [Related]
20. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.
Lachenmayer A; Alsinet C; Savic R; Cabellos L; Toffanin S; Hoshida Y; Villanueva A; Minguez B; Newell P; Tsai HW; Barretina J; Thung S; Ward SC; Bruix J; Mazzaferro V; Schwartz M; Friedman SL; Llovet JM
Clin Cancer Res; 2012 Sep; 18(18):4997-5007. PubMed ID: 22811581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
